Literature DB >> 23690026

Vesicular integrity in Parkinson's disease.

Shawn P Alter1, Gina M Lenzi, Alison I Bernstein, Gary W Miller.   

Abstract

The defining motor characteristics of Parkinson's disease (PD) are mediated by the neurotransmitter dopamine (DA). Dopamine molecules spend most of their lifespan stored in intracellular vesicles awaiting release and very little time in the extracellular space or the cytosol. Without proper packaging of transmitter and trafficking of vesicles to the active zone, dopamine neurotransmission cannot occur. In the cytosol, dopamine is readily oxidized; excessive cytosolic dopamine oxidation may be pathogenic to nigral neurons in PD. Thus, factors that disrupt vesicular function may impair signaling and increase the vulnerability of dopamine neurons. This review outlines the many mechanisms by which disruption of vesicular function may contribute to the pathogenesis of PD. From direct inhibition of dopamine transport into vesicles by pharmacological or toxicological agents to alterations in vesicle trafficking by PD-related gene products, variations in the proper compartmentalization of dopamine can wreak havoc on a functional dopamine pathway. Findings from patient populations, imaging studies, transgenic models, and mechanistic studies will be presented to document the relationship between impaired vesicular function and vulnerability of the nigrostriatal dopamine system. Given the deleterious effects of impaired vesicular function, strategies aimed at enhancing vesicular function may be beneficial in the treatment of PD.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690026      PMCID: PMC4019229          DOI: 10.1007/s11910-013-0362-3

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  168 in total

1.  Rapid reuse of readily releasable pool vesicles at hippocampal synapses.

Authors:  J L Pyle; E T Kavalali; E S Piedras-Rentería; R W Tsien
Journal:  Neuron       Date:  2000-10       Impact factor: 17.173

2.  Push-and-pull regulation of the fusion pore by synaptotagmin-7.

Authors:  Margarita Segovia; Eva Alés; María Angeles Montes; Imelda Bonifas; Imane Jemal; Manfred Lindau; Anton Maximov; Thomas C Südhof; Guillermo Alvarez de Toledo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

3.  Pesticide exposure and risk for Parkinson's disease.

Authors:  Alberto Ascherio; Honglei Chen; Marc G Weisskopf; Eilis O'Reilly; Marjorie L McCullough; Eugenia E Calle; Michael A Schwarzschild; Michael J Thun
Journal:  Ann Neurol       Date:  2006-08       Impact factor: 10.422

Review 4.  Vesicular neurotransmitter transporters as targets for endogenous and exogenous toxic substances.

Authors:  Farrukh A Chaudhry; Robert H Edwards; Frode Fonnum
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

5.  Quantitative ultrastructural analysis of hippocampal excitatory synapses.

Authors:  T Schikorski; C F Stevens
Journal:  J Neurosci       Date:  1997-08-01       Impact factor: 6.167

6.  Neuronal uptake and metabolism of 2- and 6-fluorodopamine: false neurotransmitters for positron emission tomographic imaging of sympathetically innervated tissues.

Authors:  G Eisenhofer; D Hovevey-Sion; I J Kopin; R Miletich; K L Kirk; R Finn; D S Goldstein
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

7.  Polychlorinated biphenyl mixture aroclor 1254-induced oxidative stress plays a role in dopaminergic cell injury.

Authors:  D W Lee; L A Opanashuk
Journal:  Neurotoxicology       Date:  2004-12       Impact factor: 4.294

8.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

9.  Parkinson's disease and exposure to rural environmental factors: a population based case-control study.

Authors:  K M Semchuk; E J Love; R G Lee
Journal:  Can J Neurol Sci       Date:  1991-08       Impact factor: 2.104

10.  Polychlorinated biphenyl-induced reduction of dopamine transporter expression as a precursor to Parkinson's disease-associated dopamine toxicity.

Authors:  W Michael Caudle; Jason R Richardson; Kristin C Delea; Thomas S Guillot; Minzheng Wang; Kurt D Pennell; Gary W Miller
Journal:  Toxicol Sci       Date:  2006-05-15       Impact factor: 4.849

View more
  17 in total

1.  Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.

Authors:  Shawn P Alter; Kristen A Stout; Kelly M Lohr; Tonya N Taylor; Kennie R Shepherd; Minzheng Wang; Thomas S Guillot; Gary W Miller
Journal:  Exp Neurol       Date:  2015-09-30       Impact factor: 5.330

2.  Phosphorylation at serine 31 targets tyrosine hydroxylase to vesicles for transport along microtubules.

Authors:  Ana Jorge-Finnigan; Rune Kleppe; Kunwar Jung-Kc; Ming Ying; Michael Marie; Ivan Rios-Mondragon; Michael F Salvatore; Jaakko Saraste; Aurora Martinez
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

Review 3.  The vesicular monoamine transporter 2: an underexplored pharmacological target.

Authors:  Alison I Bernstein; Kristen A Stout; Gary W Miller
Journal:  Neurochem Int       Date:  2014-01-04       Impact factor: 3.921

4.  Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits.

Authors:  Aysegul O Gezer; Joseph Kochmanski; Sarah E VanOeveren; Allyson Cole-Strauss; Christopher J Kemp; Joseph R Patterson; Kathryn M Miller; Nathan C Kuhn; Danielle E Herman; Alyssa McIntire; Jack W Lipton; Kelvin C Luk; Sheila M Fleming; Caryl E Sortwell; Alison I Bernstein
Journal:  Neurobiol Dis       Date:  2020-05-15       Impact factor: 5.996

5.  Increased Vesicular Monoamine Transporter 2 (VMAT2; Slc18a2) Protects against Methamphetamine Toxicity.

Authors:  Kelly M Lohr; Kristen A Stout; Amy R Dunn; Minzheng Wang; Ali Salahpour; Thomas S Guillot; Gary W Miller
Journal:  ACS Chem Neurosci       Date:  2015-03-09       Impact factor: 4.418

6.  Developmental Dieldrin Exposure Alters DNA Methylation at Genes Related to Dopaminergic Neuron Development and Parkinson's Disease in Mouse Midbrain.

Authors:  Joseph Kochmanski; Sarah E VanOeveren; Joseph R Patterson; Alison I Bernstein
Journal:  Toxicol Sci       Date:  2019-06-01       Impact factor: 4.849

7.  Covalent Modification and Regulation of the Nuclear Receptor Nurr1 by a Dopamine Metabolite.

Authors:  John M Bruning; Yan Wang; Francesca Oltrabella; Boxue Tian; Svetlana A Kholodar; Harrison Liu; Paulomi Bhattacharya; Su Guo; James M Holton; Robert J Fletterick; Matthew P Jacobson; Pamela M England
Journal:  Cell Chem Biol       Date:  2019-03-07       Impact factor: 8.116

Review 8.  Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease.

Authors:  Christopher L German; Michelle G Baladi; Lisa M McFadden; Glen R Hanson; Annette E Fleckenstein
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

9.  Immunochemical localization of vesicular monoamine transporter 2 (VMAT2) in mouse brain.

Authors:  Rachel A Cliburn; Amy R Dunn; Kristen A Stout; Carlie A Hoffman; Kelly M Lohr; Alison I Bernstein; Emily J Winokur; James Burkett; Yvonne Schmitz; William M Caudle; Gary W Miller
Journal:  J Chem Neuroanat       Date:  2016-11-09       Impact factor: 3.052

10.  Fungal-derived semiochemical 1-octen-3-ol disrupts dopamine packaging and causes neurodegeneration.

Authors:  Arati A Inamdar; Muhammad M Hossain; Alison I Bernstein; Gary W Miller; Jason R Richardson; Joan Wennstrom Bennett
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.